CAMBRIDGE, Mass.--(OvaScienceSM, (OTC: OVSC), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, today announced that Co-Founder Jonathan L. Tilly, Ph.D., and Chief Scientific Officer Scott Chappel, Ph.D., are featured speakers at the 15th World Congress on Human Reproduction being held in Italy this week. Dr. Tilly will present the Congress opening lecture, and Dr. Chappel will give a presentation on OvaScience’s approach to addressing unmet needs in the clinical management of female infertility.)--
“ART: From the Lab to the Clinics”
Dr. Tilly, a Massachusetts General Hospital-based Professor of Obstetrics, Gynecology and Reproductive Biology at Harvard Medical School and Affiliated Faculty Member of the Harvard Stem Cell Institute in Boston, will present the Opening Lecture on Wednesday, March 13, titled “Ovarian Aging: Can Science Turn Back the Clock?” As Dr. Tilly reported in Nature Medicine last year, one of the most significant recent advances in this emerging field was his lab’s demonstration that egg precursor cells (EggPCSM) exist in the ovaries of reproductive-age women and have the ability to produce new immature egg cells. In as-yet unpublished work, Dr. Tilly has found that these cells persist in ovaries with advancing age, even when oocyte loss is complete. Based on these and other observations, Dr. Tilly is exploring the possibility that ovarian failure due to aging or other causes is preventable, if not reversible, by targeting EggPCs. In his presentation, Dr. Tilly will highlight novel strategies using EggPCs, being developed in his lab and by OvaScience, to address the aging-related decline in both available egg numbers and overall egg quality as a means to improve in vitro fertilization (IVF) outcomes.
On Saturday, March 16, Dr. Chappel will participate in the “ART: From the Lab to the Clinics” track with a talk titled “From Oocyte Fertilization to Implantation: Role of Mitochondria”. Dr. Chappel’s presentation will provide the scientific background for mitochondrial augmentation of the oocyte, and a description of the process used to isolate mitochondria within an IVF patient’s own EggPCs, all of which led to the development of OvaScience’s first product candidate, AUGMENTSM.
Michelle Dipp, M.D., Ph.D., Chief Executive Officer of OvaScience commented, “The World Congress on Human Reproduction attracts world-leading scientists and clinicians who are working in their respective countries to advance our collaborative agenda to make progress in the science of human reproduction. We are delighted that the foundational science for OvaScience’s approach to developing new treatments for infertility will be featured this year.”
OvaScience (OTC: OVSC) is a life sciences company focused on the discovery, development and commercialization of new treatments for infertility. The Company’s patented technology is based on the discovery of egg precursor cells (EggPCSM), which are found in the ovaries. By applying proprietary technology to identify and purify EggPCs, AUGMENTSM aims to improve egg quality and increase the success of in vitro fertilization (IVF). OvaScience’s team of scientists, physicians and advisers includes recognized leaders in the field of reproductive medicine. For more information, please visit www.ovascience.com.
This press release includes forward-looking statements about the Company’s strategy, future plans and prospects, including statements regarding the development of the Company’s product candidates, including AUGMENT. Any statements in this release about our strategy, plans, prospects and future expectations, financial position and operations, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” ”aim,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: our expectations regarding the regulatory approvals required for AUGMENT; the science underlying our two product candidates, which is unproven; our ability to obtain, maintain and protect intellectual property utilized by our products; our ability to obtain additional funding to support our activities; our dependence on third parties; the successful development of, and ability to obtain regulatory approval for, our product candidates; our ability to commercialize our product candidates, including AUGMENT, on the timeline we expect, if at all; competition from others; and our short operating history; as well as those risks more fully discussed in the “Risk Factors” section of our most recently filed Quarterly Report on Form 10-Q or Annual Report on Form 10-K. The forward-looking statements contained in this press release reflect our current views with respect to future events. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our view as of any date subsequent to the date hereof.